FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma

Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers

Majid Assadi, Seyed Javad Rekabpour, Esmail Jafari et al. · Clinical Nuclear Medicine · 2021 · 157 citations

Medicine, Nuclear Medicine, Oncology +17

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy

Sanjana Ballal, Madhav Prasad Yadav, Vasko Kramer et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 124 citations

Medicine, Nuclear Medicine, Radiology +16

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Jérémie Calais · Journal of Nuclear Medicine · 2020 · 118 citations · Full text

Medicine, Nuclear Medicine, Pharmaceutics +14

Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients

Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler et al. · Journal of Nuclear Medicine · 2021 · 115 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study

Justin Ferdinandus, Wolfgang P. Fendler, Andrea Farolfi et al. · Journal of Nuclear Medicine · 2021 · 34 citations · Full text

Medicine, Nuclear Medicine, Oncology +17